Crohn-betegség: vizsgálatok itt: Németország
40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
- Where
- Berlin, Brandenburg An Der Havel, Duisburg, Hanover, Kiel, Leipzig, Ludwigshafen am Rhein, Lueneburg, Minden, Munich, Pforzheim, Remscheid, Rostock, Ulm
- Életkor
- 18 év and over
- People
- 567 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Berlin, Brandenburg An Der Havel, Duisburg, Hanover, Kiel, Leipzig, Ludwigshafen am Rhein, Lueneburg, Minden, Munich, Pforzheim, Remscheid, Rostock, Ulm
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 1. fázisNot yet taking people in NémetországAn Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
- Where
- Berlin, Cottbus, Munich, Ulm
- Életkor
- 18 év to 65 év
- People
- 25
- Run by
- Sanofi
See details and how to joinNCT07923383 · EU 2026-525939-17-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Berlin, Dachau, Duisburg, Frankfurt am Main, Halle (Saale), Heidelberg, Kiel, Leipzig, Magdeburg, Munich, Wipperfuerth, Wolfsburg
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 2. fázisTaking peopleA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Where
- Berlin, Dachau, Halle (Saale), Ludwigshafen am Rhein, Ulm
- Életkor
- 18 év to 80 év
- People
- 60 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00 - 2. fázisTaking peopleA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Where
- Berlin, Dachau, Halle, Ludwigshafen, Ulm
- Életkor
- 18 év to 80 év
- People
- 60 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07483099 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Hamburg, Sankt Augustin
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - No phaseTaking peopleA Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
- Where
- Berlin
- Életkor
- 18 év and over
- People
- 500
- Run by
- Janssen-Cilag G.m.b.H
See details and how to joinNCT07102368 - 2/3. fázisTaking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Berlin, Dachau, Erlangen, Halle (Saale), Hanover, Jerichow, Kiel, Leipzig, Lueneburg, Oldenburg in Holstein, Rostock, Ulm
- Életkor
- 18 év and over
- People
- 1092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - 3. fázisTaking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Berlin, Erlangen, Grevenbroich, Jena, Kiel, Ludwigshafen am Rhein, Mannheim, München
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Augsburg, Berlin, Dachau, Dresden, Erlangen, Frankfurt Am Main, Halle (Saale), Halle Saale, Hanover, Kassel, Kiel, Leipzig, Mannheim, Munich, Regensburg, Rostock, Ulm
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - 2. fázisTaking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Frankfurt am Main, Frankfurt Am Main, Kiel, Ludwigshafen am Rhein, Mannheim, Tuebingen, Ulm
- Életkor
- 18 év to 75 év
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Where
- Jena, Kiel, Minden, Potsdam, Ulm
- Életkor
- 18 év to 75 év
- People
- 99 worldwide
- Run by
- Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00 - 4. fázisTaking peopleA study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication
- Where
- Frankfurt
- People
- 16 worldwide
- Run by
- Eli Lilly & Co.
See details and how to join2025-522362-78-00 · EU 2025-522362-78-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Berlin, Heidelberg, Jena, Potsdam, Ulm
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Berlin, Dachau, Dresden, Duisburg, Halle, Hamburg, Herne, Jerichow, Kiel, Leipzig, Ludwigshafen am Rhein, Lüneburg, Minden, Remscheid, Tübingen, Ulm, Würzburg
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Kiel, Leipzig, Ulm
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Muenster, Munich
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Berlin, Frankfurt am Main, Frankfurt Am Main, Halle Saale, Hanover, Jena, Ulm
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 2. fázisTaking peopleA clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
- Where
- Berlin, Frankfurt am Main, Munich, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00 - No phaseTaking peopleImpact of Diet and Lifestyle Modification on the Intestinal Barrier Integrity in Crohn's Disease
- Where
- Bamberg
- Életkor
- 18 év and over
- People
- 30
- Run by
- Universität Duisburg-Essen
See details and how to joinNCT06719778 - 3. fázisTaking peopleA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Where
- Mainz, Munich
- Életkor
- 2 év to 19 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT04844606 - No phaseTaking peopleWild Blueberries in Colitis
- Where
- Bamberg
- Életkor
- 18 év and over
- People
- 60
- Run by
- Universität Duisburg-Essen
See details and how to joinNCT06698601 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Fulda, Halle (Saale), Homburg, Kiel, Leipzig, Ludwigshafen am Rhein, Lueneburg, Mannheim, Munich, Regensburg, Ulm
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00